The pricing of Mustang Bio's public offering at $0.237 per share, significantly below market value, could lead to dilution of existing shares. However, the capital raised is crucial for ongoing operations and development, indicating a mixed impact on the stock's short-term performance. The introduction of warrants exercisable upon stockholder approval adds another layer of potential dilution but also indicates a pathway for additional capital infusion.